Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration

Author(s):  de Villiers Melgardt M, Vogel Laura, Bogenschutz Monica C, Fingerhut Bonnie J, D'Silva Joseph B, Moore Anne

Issue:  May/Jun 2010 - Pain Management
View All Articles in Issue

Page(s):  250-256

Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Page 1
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Page 2
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Page 3
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Page 4
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Page 5
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Page 6
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Page 7

Download in electronic PDF format for $75

Abstract:  Often medications that have to be administered to patients via a nasogastric enteral feeding tubes are only available as tablets and capsules with no suitable commercial liquids alternatives. In such situations, pharmacists and nurses have to compound the tablets and capsule contents into liquid suspension formulations for dosing. The risk of occlusion of the enteral tubes during administration is reduced by employing liquid suspensions that are composed of small and uniform particles, not subject to rapid rates of settling, resistant to caking, and easily and uniformly resuspended upon agitation. Present techniques often employ a manual process, such as a mortar and pestle, to accomplish the particle size reduction and subsequent incorporation into a suitable liquid diluent. A new compounding device has been invented that employs an automated wet-milling process in a single-use disposable plastic container to compound the suspensions. The two processes were compared using Rifampin capsules and various liquid

Related Keywords: Anne Moore, Ingenieur ENSCP, DEA, nasogastric enteral feeding tube, liquid suspension preparations, rifampin, antibiotic, antimicrobial agent, antitubercular agent, tuberculosis, nasogastric tube injectability test, particle size, tube blockage

Related Categories: FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, QUALITY CONTROL, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration
de Villiers Melgardt M
, Vogel Laura, Bogenschutz Monica C, Fingerhut Bonnie J, D'Silva Joseph B, Moore Anne
May/Jun 2010
Pg. 250-256

Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes
Allen Loyd V Jr
May/Jun 2022
Pg. 214-217

Recommendations for Compounding Medications for Feeding Tube Administration
Klang Mark
Jul/Aug 2010
Pg. 276-282

Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube
Allen Loyd V Jr
Jul/Aug 2021
Pg. 320

Nasogastric Tube/Percutaneous Endoscopic Gastrostomy Tube Suspension Formula
Allen Loyd V Jr
Jul/Aug 2000
Pg. 304

Fluconazole 1-mg/mL Liquid for Nasogastric Tube Administration
Allen Loyd V Jr
Sep/Oct 2006
Pg. 383

Technology Spotlight: Tube Sealers
Jones Michael
, Adams Susan
May/Jun 2003
Pg. 206-207

Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Allen Loyd V Jr
Nov/Dec 2016
Pg. 495-500

Rifampin 25 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
Jul/Aug 2019
Pg. 319

Hazardous Drug Enteral Device: A Closed System Device for Crushing and Dispersing Hazardous Drug Tablets for Enteral Administration
Lopez C Vidal
, Rios GL Quito
Sep/Oct 2022
Pg. 358-362

Rifampin 300-mg and Isoniazid 150-mg Capsules
Allen Loyd V Jr
Jul/Aug 2013
Pg. 334

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Glaser Rebecca L
, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
Jul/Aug 2009
Pg. 314-317

Stability of Rifampin in SyrSpend SF
Sorenson Bridget
, Whaley Paul
Mar/Apr 2013
Pg. 162-164

Rifampin 10-mg/mL Nasal Drops
Allen Loyd V Jr
Jul/Aug 2023
Pg. 328

Rifampin 10-mg/mL Oral Suspension
Allen Loyd V Jr
Mar/Apr 2003
Pg. 132

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 11: Drug Tastes: Innate, Induced, and Improved
Allen Loyd V Jr
Sep/Oct 2021
Pg. 396-400

Erythromycin 400-mg/mL and Rifampin 50-mg/mL Oral Liquid
Allen Loyd V Jr
Sep/Oct 2002
Pg. 367

Stability of Allopurinol Suspension Compounded from Tablets
Alexander Kenneth S
, Davar Nipun, Parker Gordon A
Mar/Apr 1997
Pg. 128-131

Return to Top